Skip to main content
Clinical Trials/CTRI/2021/11/038256
CTRI/2021/11/038256
Not yet recruiting
Phase 3

An Open-label, Single-arm clinical study to evaluate the Efficacy and Safety of Rumalaya Cream in common Musculoskeletal conditions

Himalaya Wellness Company0 sites0 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: M00-M99- Diseases of the musculoskeletal system and connective tissue
Sponsor
Himalaya Wellness Company
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Subjects of either gender aged \>\=18 \- \<\=65 years.
  • 2\.Subjects presenting with pain due to common musculoskeletal conditions inclusive of any of the below:
  • a Joints pain,
  • b Neck pain inclusive of Cervical spondylosis
  • c Shoulder pain inclusive of Frozen Shoulder
  • d Low back pain inclusive of Lumbar spondylosis
  • e Muscular pain
  • f Muscular sprain.
  • 3\.Subjects who are willing to refrain any topical applications during the study period.
  • 4\.Subjects who are not on NSAIDs in the past 24 hours prior to screening.

Exclusion Criteria

  • 1\.Subjects suffering from auto\-immune disorders, spastic disorders, genetic disorders and severe traumatic conditions.
  • 2\.Any evidence or history of hypersensitivity to any of the components in the Rumalaya cream.
  • 3\.Any known skin disorder or presence of open wounds.
  • 4\.Subjects who are on opioid analgesics and steroid medication will be excluded.
  • 5\.Clinical diagnosis of bruises, trauma, muscle damage.
  • 6\.Subjects with raw wounds, sutures, fractures and hematoma.
  • 7\.Pregnant or lactating women/women not willing to follow adequate standard contraceptive measures.

Outcomes

Primary Outcomes

Not specified

Similar Trials